Objectives: With the aim to develop a PET tracer to visualize P-glycoprotein (Pgp) expression levels in different organs, the Pgp inhibitor MC113 was labeled with 11 C and evaluated using small-animal PET. Methods: [ 
Introduction
The adenosine triphosphate (ATP) binding cassette (ABC) transporter P-glycoprotein (Pgp) is expressed in the luminal membrane of the small intestine and blood-brain barrier (BBB), and in the apical membranes of excretory cells such as hepatocytes and kidney proximal tubule epithelia [1] . Pgp actively transports a wide range of structurally diverse, mostly lipophilic compounds against concentration gradients and may therefore exert a significant impact on absorption, distribution and excretion of drug molecules [2] . Moreover, Pgp-mediated efflux transport of chemotherapeutic drugs out of tumor cells is an important mechanism contributing to chemoresistance of tumors [3] . Apart from its well established role in tumor resistance, changes in Pgp expression and function are also believed to occur in several neurological disorders, such as epilepsy, Alzheimer's and Parkinson's disease [1] .
Positron emission tomography (PET) is a potentially powerful method to non-invasively study disease related alterations in Pgp functionality and density in different organs such as the brain provided the availability of suitable radiotracers for Pgp. Most PET tracers for Pgp investigated in humans so far are high-affinity Pgp substrates, such as racemic [ BBB after pharmacological inhibition of Pgp with inhibitors, such as tariquidar or cyclosporine A, their low brain uptake makes the assessment of more subtle alterations in Pgp function/expression as they may occur in distinct brain regions during the progression of disease very challenging [4] [5] [6] .
As an alternative to radiolabeled Pgp substrates, radiolabeled Pgp inhibitors, such as [ 11 C]laniquidar [7] , [ 11 C]tariquidar [8, 9] , [ 11 C] elacridar [10, 11] [13] , have been proposed. It was expected that such probes would bind to Pgp rather than being transported by Pgp and thereby allow for mapping of Pgp density and afford higher PET signals than radiolabeled substrates. Unexpectedly, these probes were found to display very low brain uptake in rodents, most likely because they were recognized by Pgp and breast cancer resistance protein (Bcrp), another ABC transporter expressed at the BBB, as substrates [14, 15] , making them unsuitable to measure Pgp density at the BBB.
Recently, a series of new potent Pgp inhibitors, which share with tariquidar and elacridar the basic 6,7-dimethoxytetrahydroisoquinoline nucleus, has been described ( Fig. 1) [16] . One of these compounds, 6,7-dimethoxy-2-{3-[4-methoxy-3,4-dihydro-2H naphthalen-(1E)-ylidene]-propyl}-1,2,3,4-tetrahydro-isoquinoline (MC18, Fig. 1 [18] , which all showed increases in brain uptake as compared with baseline scans following pretreatment of rats or mice with the respective unlabeled compounds, presumably due to inhibition of Pgp/Bcrp efflux of these radiotracers by cold compound.
Starting from MC18 as lead, 6,7-dimethoxy-2-(4-methoxy-biphenyl-4-yl-methyl)-1,2,3,4-tetrahydro-isoquinoline (MC70, Fig. 1 ) mice as well as in a recently described mouse model of high and low Pgp expressing tumor grafts [20] . Data obtained with [ 11 C]MC113 were directly compared with data which we have previously obtained with [
11 C]tariquidar using the same in vivo models [9, 20] .
Materials and methods

General
Chemicals were purchased from Sigma-Aldrich Chemie GmbH (Schnelldorf, Germany) or Merck (Darmstadt, Germany) at analytical grade and used without further purification. Tariquidar dimesylate and elacridar hydrochloride were synthesized at the Department of Medicinal Chemistry (University of Vienna, Austria). Tariquidar dimesylate was freshly dissolved in 2.5% (w/v) aqueous (aq.) dextrose solution prior to each administration and intravenously (i.v.) injected into animals at a volume of 4 mL/kg. MC113, MC70 and MC18 were synthesized at the Department of Pharmacy (University of Bari, Bari, Italy) as described previously [16, 19] , animals underwent PET imaging. The study was approved by the local animal welfare committee and all study procedures were performed in accordance with the Austrian Animal Experiments Act. All efforts were made to minimize both the suffering and the number of animals used in this study. After heating for 4 min at 60°C the reaction mixture was cooled (25°C), diluted with water (0.5 mL) and injected into a built-in high-performance liquid chromatography (HPLC) system equipped with a Chromolith Performance RP18e (100-4.6 mm) column (Merck KGaA) which was eluted with acetonitrile/methanol/water (45/10/145, v/v/v) at a flow rate of 4 mL/min. The HPLC eluate was monitored in series for radioactivity and ultraviolet (UV) absorption at a wavelength of 227 nm. On this system, radiolabeling precursor MC70 and product [ 11 C]MC113 eluted with retention times of 1.5-3 min and 7-10 min, respectively. The product fraction collected from HPLC was diluted with water (100 mL) and passed over a C18 Sep-Pak Plus cartridge (Waters, Milford, MA, USA), which had been preactivated with ethanol (5 mL) and water (10 mL). The cartridge was then washed with water (10 mL) followed by elution of [ 
Experimental design for PET imaging
Two different experimental settings were used in this study. In the first set of experiments, female FVB wild-type and Mdr1a/b Fig. 2 ). Scan 1 (150 min), during which cold tariquidar (15 mg/ kg) was injected i.v. at 60 min after radiotracer injection, was followed by scan 2 (60 min), which was recorded at 120 min after cold tariquidar administration. At the end of scan 2, a 20-min static [ 18 F]FDG scan was performed to facilitate definition of tumor regions of interest (ROI) (Fig. 2 ).
PET imaging
Prior to each experiment, the animals were placed in an induction box and anaesthetized with 2.5% isoflurane. During the imaging period anesthesia was maintained with 1-2% isoflurane administered via a cone mask and the isoflurane level was adjusted depending on the depth of anesthesia. Animal respiratory rate and body temperature were constantly monitored during the data acquisition period (SA Instruments Inc, Stony Brook, NY, USA). The animals were kept warm throughout the experiment at approximately 38°C. Mice were positioned in a custom-made imaging chamber and the lateral tail vein was cannulated for i.v. administration. For PET imaging a microPET Focus220 (Siemens Medical Solutions, Knoxville, USA) was used. [ was injected over approximately 60 s in a volume of 0.1 mL followed by a 20-min static PET scan (see Fig. 2 ). For all groups of animals, list-mode data were acquired for the defined time period with an energy window of 250-750 keV and a 6 ns timing window. Before each PET scan, a transmission scan using a 57 Co point source was recorded for 10 min. After completion of the imaging procedure, animals were sacrificed by cervical dislocation while still under deep anesthesia. In tumor bearing animals tumors were excised and snap frozen in liquid nitrogen and stored at −80°C until Western blot analysis of Pgp expression levels as described in detail elsewhere [20] .
PET data analysis
The dynamic PET data were sorted into three-dimensional sinograms. Images were reconstructed using Fourier rebinning of the 3-D sinograms followed by two-dimensional filtered backprojection. The standard data correction protocol (normalization, decay correction and injection decay correction) was applied to the data. Tumor ROIs were manually outlined over multiple planes in the static [ 18 F]FDG scans and whole brain ROIs were outlined in the PET summation images of scan 1. ROIs were used to generate volumes of interest (VOI), which were then transferred to the PET images of the individual time frames. Time-activity curves (TAC), expressed as standardized uptake value (SUV=(radioactivity per cubic centimeter/injected radioactivity) x body weight), were calculated for each VOI and areas under the TACs from 0 to 60 min after radiotracer injection (AUC 0-60 ) were calculated.
Analysis of metabolites of [ 11 C]MC113
A separate group of FVB wild-type mice (n=3), which did not undergo PET scanning, was injected under isoflurane-anesthesia with [ 11 C]MC113 (70±3 MBq in a volume of approximately 0.1 mL) for metabolite analysis. Animals remained under anesthesia, were sacrificed at 30 min after radiotracer injection and a terminal blood sample (0.5 mL) was collected. Blood was centrifuged to obtain plasma (10000 × g, 5 min, 21°C), measured for radioactivity in a gamma counter (Perkin Elmer Instruments, Wellesley, USA) and analyzed for radiolabeled metabolites of [ 11 C]MC113 using a modified version of a previously described solid-phase extraction assay [22] . In brief, arterial plasma was diluted with water (0.5 mL) and acidified with 5 M aq. HCl (80 μL) and loaded on a Sep-Pak vac tC18 cartridge (Waters Corporation, Milford, USA), which had been preactivated with methanol (3 mL) and water (5 mL). The cartridge was first washed with water (4 mL) and then eluted with methanol (4 mL). Radioactivity in all three fractions (plasma, water, methanol) was measured in the gamma counter. All three fractions were then further analyzed by thin-layer chromatography (TLC) using Merck silica gel 60 F 254 plates with ethyl acetate as mobile phase. TLC plates were analyzed using a phosphor imager (Cyclone, Packard Instruments, Meriden, CN, USA). For validation of the solid-phase extraction assay, [ 11 C]MC113 dissolved in water or mouse plasma (0.5 mL) was subjected to the solid-phase extraction procedure showing that all radioactivity was quantitatively recovered in the methanol fraction.
Rhodamine 123 efflux inhibition assay
Half-maximum inhibitory concentrations (IC 50 ) were determined in a modification of a previously described method [23] . Briefly, cells expressing wild-type Pgp (CCRF-CEM T lymphoblast cell line designated CCRFvcr1000) [24] were sedimented, the supernatant was removed by aspiration, and the cells were resuspended in Dulbecco's Modified Eagle's Medium (DMEM) containing rhodamine 123 at a final concentration of 0.2 μg/mL (0.53 μM). Cells were loaded with fluorochrome for 30 min at 37°C. Tubes were chilled on ice and cells were harvested at 500 × g in an Eppendorf 5403 centrifuge (Eppendorf, Hamburg, Germany). The cell pellet was washed with ice cold DMEM medium (pH 7.4) and again centrifuged at 500 × g. After resuspension, aliquots of the cell suspension, each containing approximately 1×10 6 cells were transferred to individual fluorescence-activated cell sorter (FACS) tubes and again centrifuged. Supernatants were removed and the pellets were resuspended individually in prewarmed DMEM medium (pH 7.4) containing either no inhibitor or inhibitor (MC113, MC70, MC18, elacridar hydrochloride, tariquidar dimesylate) at various concentrations in DMSO. Each inhibitor concentration was measured in duplicate. Right after resuspending cells each individual tube was placed in a temperature controlled unit and cell associated fluorescence was monitored over a period of 5 min with a flow cytometer (FACSCalibur, Becton Dickinson, Vienna, Austria). Exponential curves were fitted to the data points and first order rate constants were determined according to the equation:
where y is the fluorescence at time t, a is the initial loading, e is the Euler number, k is the first order rate constant, t is the time in seconds and c is the background fluorescence of cells at infinite time. The first order rate constants k, which are independent of initial loading, were used to generate concentration-response curves from which the IC 50 values were calculated as 50% occupancy values using the method of least squares using nonlinear regression analysis using the solver add in of the excel software package. At least three individual experiments were performed in duplicate.
Statistical analysis
Differences between tumor and brain AUC 0-60 values in scan 1 and scan 2 were analyzed by a two-sided Wilcoxon matched pairs signed rank test using PRISM 5 software (GraphPad Software Inc., La Jolla, CA, USA). Differences in AUC 0-60 values between FVB wild-type and Mdr1a/b (−/−) mice were analyzed using a Mann Whitney test. The level of statistical significance was set to Pb0.05.
Results
Radiosynthesis of [ 11 C]MC113
O-desmethyl-MC113 (MC70, free base), which had been synthesized as described before [19] (Fig. 4) . In Fig. 2 , a diagram of the study set-up is shown. EMT6 and EMT6Ar1.0 tumors were clearly visible in the PET images (Fig. 5C ). Both in scan 1 and scan 2, TACs of [
11 C]MC113 were higher in EMT6 than in EMT6Ar1.0 tumors (Fig. 5A,B) . However, AUC 0-60 values were not significantly different between the two tumor types, both in scan 1 and scan 2 (mean±SD AUC 0-60 , scan 1: EMT6: 76±19 min, EMT6Ar1.0: 65±6 min, P=0.313; scan 2: Fig. 4 . Representative Western blot analysis of Pgp (170 kDa) in EMT6 and EMT6Ar1.0 derived tumors excised at the end of PET imaging. Expression of Pgp was assessed using the monoclonal antibody C219. Identical amounts of tumor protein (50 μg) were loaded in each well. Expression of β-actin was also measured to confirm consistent gel loading. EMT6Ar1.0 whole cell lysate (0.5 μg protein) with confirmed overexpression of Pgp [20] was used as positive control for Pgp. EMT6: 90±23 min, EMT6Ar1.0: 69±8 min, P=0.063, Wilcoxon matched pairs signed rank test) (Fig. 5D) . In response to tariquidar administration during scan 1, TACs in EMT6Ar1.0 and EMT6 tumors showed modest increases (Fig. 5A) . However, for both tumor types AUC 0-60 values in scan 2 were not significantly different as compared with scan 1 (Fig. 5D ). In brain, peak radioactivity uptake (1.7±0.2 SUV at 9 min after radiotracer injection) was comparable with that in tumors. However, brain TACs differed from tumor TACs in that activity cleared from brain, whereas activity continued to rise in tumor tissue during the time course of the PET scan. Comparable to tumor tissue, there was a modest increase in brain TACs in response to tariquidar administration (Fig. 5A ). Brain AUC 0-60 values were higher in scan 2 than in scan 1, although statistical significance was not reached (mean±SD AUC 0-60 , brain: scan 1: 68±7 min, scan 2: 74±7 min, P=0.063, Wilcoxon matched pairs signed rank test) (Fig. 5D ).
Inhibition of rhodamine 123 efflux by MC113
The inhibitory effects of MC113 and MC70 on Pgp-mediated efflux transport of rhodamine 123 were measured in CCRFvcr1000 cells and compared with MC18, elacridar and tariquidar (Fig. 6) . In Fig. 6A , log concentration-response curves are shown for all 5 inhibitors. 
Discussion
In search for a PET tracer which binds to Pgp without being transported by it, we labeled MC113 [19] , a structural analogue of tariquidar and elacridar (Fig. 1) was not increased but rather slightly decreased in EMT6Ar1.0 as compared with EMT6 tumors without reaching statistical significance (Fig. 5) . Due to the fact that tumors were implanted bilaterally into animals each animal served as its own control, so that activity concentrations in the two tumor types could be directly compared without the need to consider blood activity concentrations. Moreover, analysis of radiolabeled metabolites by a combined solid-phase extraction/radio-TLC assay had revealed that N90% of activity in mouse plasma at 30 min after radiotracer injection was in the form of unmetabolized [ 11 C]MC113, which suggests that PET signal measured in tumor tissue was mainly due to unmetabolized tracer. To assess Pgp-specificity of PET signal in tumor, we administered a high dose (15 mg/kg) of cold tariquidar during the first PET scan with [ 11 C]MC113 (Fig. 2) tumors, before as well as after administration of tariquidar, it seems very unlikely that it was related to a Pgp-specific mechanism. which MC70 was shown to be more potent than elacridar [19] , our data showed that MC113, MC70 and MC18 were up to two orders of magnitude less potent than tariquidar and elacridar in inhibiting rhodamine 123 transport (Fig. 6B) . The exact reasons why the Caco-2 transport inhibition and rhodamine 123 efflux inhibition assays gave different rank orders of inhibitory potencies for our compounds are not known, but could be related to the fact that different substrates were used in the two assays (vinblastine versus rhodamine 123) and that Caco-2 cells are known to express, in addition to Pgp, a range of other efflux transporters (e.g. BCRP, MRP2) [25] . When assuming that the ability to inhibit substrate transport reflects the Pgp binding affinity of an inhibitor, our rhodamine 123 efflux inhibition data could mean that the Pgp binding affinity of MC113 might be too low in relation to the density (B max ) of Pgp at the murine BBB to achieve a Pgp binding signal with [
11 C]MC113. Using a quantitative proteomics approach Kamiie and colleagues reported a B max of the Mdr1a peptide of 15 fmol/μg protein in mouse brain capillaries [26] , which translates to a value of 1.5 nM when assuming that the BBB constitutes only about 0.1% of total brain weight and that the protein content of brain capillaries is approximately 10%. This would mean that compounds with subnanomolar Pgp binding affinities would be needed to visualize Pgp at the BBB with PET and to achieve B max /K d ratios N1. Given that unlike previously developed radiolabeled Pgp inhibitors [ 11 C]MC113 did not appear to be transported to a high extent by Pgp at the BBB in vivo and also showed high metabolic stability in vivo, the compound might serve as a lead for future development of Pgp inhibitor PET tracers with improved Pgp binding affinities.
Conclusion
We evaluated the radiolabeled Pgp inhibitor [ 
